Relationship between driver gene mutations, their relative protein expressions and survival in non-small cell lung carcinoma in Macao.
作者： Kin Iong Chan , Hong Ting Vong , Lai Fong Sin , Yuk Ching Yip , Xue Yun Zhong
DOI: 10.1111/CRJ.12670
关键词:
摘要: Objectives We report the status of most common gene mutations in non-small cell lung carcinoma (NSCLC) Macao, and explore relationship between each mutation clinicopathologic features survival. Methods EGFR, KRAS BRAF were detected by PCR 122 cases NSCLC. ALK translocation MET amplification fluorescence situ hybridization (FISH). thyroid transcription factor (TTF-1) investigated immunohistochemistry. Clinical data collected for analyzing their correlation with mutations. Results The EGFR, was 48 (39.3%), 13 (10.7%) 3 (2.5%) NSCLC, respectively. 7 (5.7%) (2.5%). The rate EGFR significantly higher female non-smoker patients. In TTF-1 positive more frequent. Age patients over 62-year old correlated mutations. concordance IHC FISH 58.3%. protein 100% positive. survival lower than those negative. an independent prognostic NSCLC. Conclusions EGFR occurred frequently never smoke Negative expression could be used as a negative predictive marker amplification.
sci-hub.se 参考文章(23)
Neeta Somaiah, Mary Jo Fidler, Elizabeth Garrett-Mayer, Amy Wahlquist, Keisuke Shirai, Lela Buckingham, Thomas Hensing, Philip Bonomi, George R. Simon, Epidermal growth factor receptor (EGFR) mutations are exceptionally rare in thyroid transcription factor (TTF-1)-negative adenocarcinomas of the lung Oncoscience. ,vol. 1, pp. 522- 528 ,(2014) , 10.18632/ONCOSCIENCE.72
E Rapp, J L Pater, A Willan, Y Cormier, N Murray, W K Evans, D I Hodson, D A Clark, R Feld, A M Arnold, Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial. Journal of Clinical Oncology. ,vol. 6, pp. 633- 641 ,(1988) , 10.1200/JCO.1988.6.4.633
Steven A. Ahrendt, P. Anthony Decker, Enas A. Alawi, Yong-ran Zhu, Montserrat Sanchez-Cespedes, Stephen C. Yang, George B. Haasler, André Kajdacsy-Balla, Michael J. Demeure, David Sidransky, Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer. ,vol. 92, pp. 1525- 1530 ,(2001) , 10.1002/1097-0142(20010915)92:6<1525::AID-CNCR1478>3.0.CO;2-H
Ying Li, Yongwen Li, Tong Yang, Sen Wei, Jing Wang, Min Wang, Yuli Wang, Qinghua Zhou, Hongyu Liu, Jun Chen, Clinical Significance of EML4-ALK Fusion Gene and Association with EGFR and KRAS Gene Mutations in 208 Chinese Patients with Non-Small Cell Lung Cancer PLoS ONE. ,vol. 8, pp. e52093- ,(2013) , 10.1371/JOURNAL.PONE.0052093
Susumu Kobayashi, Titus J. Boggon, Tajhal Dayaram, Pasi A. Jänne, Olivier Kocher, Matthew Meyerson, Bruce E. Johnson, Michael J. Eck, Daniel G. Tenen, Balázs Halmos, EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib The New England Journal of Medicine. ,vol. 352, pp. 786- 792 ,(2005) , 10.1056/NEJMOA044238
Pasi A. Jänne, Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours Lung Cancer. ,vol. 60, ,(2008) , 10.1016/S0169-5002(08)70099-0
David Planchard, Identification of driver mutations in lung cancer: first step in personalized cancer Targeted Oncology. ,vol. 8, pp. 3- 14 ,(2013) , 10.1007/S11523-013-0263-Z
Bao Ming QIN, Xiao CHEN, Jing De ZHU, Duan Qing PEI, Identification of EGFR kinase domain mutations among lung cancer patients in China: implication for targeted cancer therapy Cell Research. ,vol. 15, pp. 212- 217 ,(2005) , 10.1038/SJ.CR.7290289
David R Spigel, Martin J Edelman, Tony Mok, Kenneth O'Byrne, Luis Paz-Ares, Wei Yu, Karen Rittweger, Holger Thurm, MetLung Phase III Study Group, None, Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non–Small-Cell Lung Cancer Clinical Lung Cancer. ,vol. 13, pp. 500- 504 ,(2012) , 10.1016/J.CLLC.2012.05.009
Lecia V. Sequist, Renato G. Martins, David Spigel, Steven M. Grunberg, Alexander Spira, Pasi A. Jänne, Victoria A. Joshi, David McCollum, Tracey L. Evans, Alona Muzikansky, Georgiana L. Kuhlmann, Moon Han, Jonathan S. Goldberg, Jeffrey Settleman, A. John Iafrate, Jeffrey A. Engelman, Daniel A. Haber, Bruce E. Johnson, Thomas J. Lynch, First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutations Journal of Clinical Oncology. ,vol. 26, pp. 2442- 2449 ,(2008) , 10.1200/JCO.2007.14.8494